Resumo

GARCIA OSORNO, Zurisadai Raquel et al. COVID-19 vaccines. Acta méd. Grupo Ángeles [online]. 2021, vol.19, n.3, pp.429-444.  Epub 04-Abr-2022. ISSN 1870-7203.

The appearance of the SARS-CoV-2 virus has generated a high degree of mortality and severe morbidity around the world, leading to the COVID-19 pandemic. This situation led to the emergence and development of different vaccines to prevent severe disease due to such malaise, as well as to reduce the number of deaths worldwide. The development of current COVID-19 vaccines is based on four platforms: genetic material of the virion, previously known viral vectors, inactivated SARS-CoV-2 virion, or including antigenic proteins of the virion, all of them capable of generating neutralising antibodies against the infection. These vaccines have gone through different phases of research, which have determined the effectiveness, safety, and immunogenicity of each one, as well as their use and approval by the World Health Organisation (WHO) and the different health regulatory agencies in each country. Among the vaccines currently accepted by the WHO for emergency use to control the pandemic are those manufactured by the companies Pfizer-BioNTech, Oxford-AstraZeneca, Johnson & Johnson, Moderna, Sinopharm and Sinovac.

Palavras-chave : SARS-CoV-2; COVID-19; vaccines.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )